Minou Tran, MD
Endocrinology, Diabetes & Metabolism · Pico Rivera, CANPI 1538137054
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $529,320 of the $663,025 with a category attached, or 79.8%. 53 manufacturers reported payments, led by Novo Nordisk at 36.4% of the total. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,070 payments — averaging $320.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$241K
- Lilly USA, LLC$169K
- Bayer$50K
- AstraZeneca$33K
- Merck$33K
- Corcept Therapeutics$31K
- plus $107K from 47 others
What the payments were for
- Consulting fees$35,8085%
- Speaking & faculty fees$529,32080%
- Travel & lodging$58,3679%
- Food & beverage$39,4076%
- Education$650%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$134,712
- Ozempic$89,803
- TRULICITY$63,128
- JARDIANCE$62,959
- Kerendia$48,579
- STEGLATRO$31,644
- FARXIGA$31,002
- Korlym$28,837
- BAQSIMI$26,169
- Adempas$23,365
- ZEPBOUND$20,240
- DEXCOM G7 GSS (161)$18,068
- RECORLEV$12,606
- Yorvipath$11,717
- DEXCOM G6 TRANSMITTER$6,746
- Tresiba$6,147
- UPLIZNA$3,825
- INVOKANA$3,060
- GVOKE HYPOPEN$945
- TEPEZZA$934
How this compares
$663,025 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 785 | $866,794 |
| KorlymMifepristone | 12 | $777,216 |
| JardianceEmpagliflozin | 643 | $602,146 |
| TrulicityDulaglutide | 308 | $324,388 |
| FarxigaDapagliflozin Propanediol | 278 | $254,265 |
| KerendiaFinerenone | 159 | $160,722 |
| RybelsusSemaglutide | 104 | $147,784 |
| MounjaroTirzepatide | 133 | $147,479 |
| JanuviaSitagliptin Phosphate | 101 | $102,986 |
| AfrezzaInsulin Regular, Human | 49 | $97,766 |
| ProliaDenosumab | 34 | $55,835 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 64 | $42,247 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 105 | $38,256 |
| InvokanaCanagliflozin | 45 | $35,572 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $30,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $241,022 | $1,020,405901 claims |
| Corcept TherapeuticsKorlym | $30,601 | $777,21612 claims |
| Boehringer IngelheimJardiance, Tradjenta | $25,450 | $610,303655 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $168,928 | $477,229469 claims |
| AstraZenecaFarxiga | $32,653 | $254,265278 claims |
| BayerKerendia | $49,859 | $160,722159 claims |
| MerckJanuvia, Janumet | $32,609 | $115,954122 claims |
| Mannkind CorporationAfrezza | $1,255 | $97,76649 claims |
| AmgenProlia | $10,901 | $55,83534 claims |
| Johnson & JohnsonInvokana | $3,474 | $35,57245 claims |
| AbbVieSynthroid | $621 | $8,611105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Pico Rivera
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
- Athena Philis-Tsimikasla Jolla$574K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.